Puma Biotechnology News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

19.08.20	Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL Trial in Annals of Oncology (Businesswire)
10.08.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.08.20	Puma Biotechnology Reports Second Quarter 2020 Financial Results (Businesswire)
05.08.20	Ausblick: Puma Biotechnology legt die Bilanz zum abgelaufenen Quartal vor (finanzen.net)
27.07.20	Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers (Businesswire)
23.07.20	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
09.07.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.06.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
08.05.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.05.20	Puma Biotechnology Reports First Quarter 2020 Financial Results (Businesswire)
07.05.20	Ausblick: Puma Biotechnology veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
06.05.20	Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 (Businesswire)
30.04.20	Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea (Businesswire)
23.04.20	Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results (Businesswire)
03.04.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
25.03.20	Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.03.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
28.02.20	Puma Biotechnology to Present at Cowen’s Annual Health Care Conference (Businesswire)
26.02.20	Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
20.02.20	Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results (Businesswire)
19.02.20	Ausblick: Puma Biotechnology vermeldet Zahlen zum jüngsten Quartal (finanzen.net)
07.02.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.02.20	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results (Businesswire)
13.01.20	Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference (Businesswire)
09.01.20	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
07.01.20	Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference (Businesswire)
16.12.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
14.12.19	Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS (Businesswire)
12.12.19	plasmaMATCH Trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer (Businesswire)
12.12.19	GILD's KTE-X19 To Face FDA, NTEC Drops As NVS Walks Away, KZIA On Watch (RTTNews)
12.12.19	Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium (Businesswire)
02.12.19	Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries (Businesswire)
06.11.19	Puma Biotechnology Reports Third Quarter 2019 Financial Results (Businesswire)
04.11.19	Puma Biotechnology to Present at the Credit Suisse Healthcare Conference (Businesswire)
23.10.19	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Businesswire)
03.10.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
02.10.19	FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer (Businesswire)
25.09.19	Puma Biotechnology to Present at Cantor Global Healthcare Conference (Businesswire)
11.09.19	Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
05.09.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.09.19	Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference (Businesswire)
03.09.19	FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases (Businesswire)
08.08.19	Puma Biotechnology Reports Second Quarter 2019 Financial Results (Businesswire)
06.08.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
06.08.19	Ausblick: Puma Biotechnology präsentiert Quartalsergebnisse (finanzen.net)
25.07.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
24.07.19	Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results (Businesswire)
03.07.19	Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019 (Businesswire)
01.07.19	Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer (Businesswire)
05.06.19	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Puma Biotechnology Inc

Aktien Top/Flop

Meistgelesene Nachrichten